Table 4.
Deposition fractions (as a percentage of aerosolized dose) based on CFD predictions compared with the in vivo data of Newman et al. (52) (in parentheses) for the Respimat SMI operated with a SD waveform and PIFR of 41.2 LPM.
| Device | NA (21.9) |
| MT | 39.5 (37.1) |
| Central lung (trachea excluded) | 9.1 (11.0) |
| Intermediate and peripheral lung | 28.7 (28.2) |
| Trachea-B3 | 1.0 |
| B4-B7 | 8.9 |
| B8-B15 | 9.2 |
| Alveolar | 19.5 |